Anti-TGF-beta Therapy in Patients With Myelofibrosis

Stopped Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.

Conditions

• Myelofibrosis
• Primary Myelofibrosis
• Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
• Post-essential Thrombocythemia Related Myelofibrosis

Interventions

• BIOLOGICAL: monoclonal antibody to TGF-beta

Sponsor

John Mascarenhas